SHARE NOW
In this interview, Ohad Karnieli, Founder and CEO of ADVA Biotechnology, explains the different areas AI & sensing can have an impact within the realm of cell therapy, paying special attention to the effect on price and availability of cell therapies.
Ohad begins by explaining what AI & sensing means in the context of cell manufacturing, explaining the crucial difference between describing technologies as ‘evolutionary’ vs ‘revolutionary’.
Ohad goes on to explore the use of AI & metabolic sensing for autologous manufacturing, as well as how AI & sensor-based cell manufacturing influences quality, before explaining how both AI and sensor-based cell manufacturing can have an overall impact on the price and availability of cell therapies.
If you are joining us at Advanced Therapies Week 2023, make sure to visit Adva at their beach hut booth! Not yet registered? Get your tickets here >>
This interview has been produced in partnership with Adva Biotechnology, ahead of Advanced Therapies Week 2023.
 |
 |
More like this
Eureka Therapeutics Awarded $10.6M CIRM Grant for T-Cell Therapy in Pediatric Liver Cancer
Cell and Gene Therapy Catapult Open New Edinburgh, UK, Facilities
BioCentriq® Unveils LEAP™ Advanced Therapy Platform, Enabling Rapid Patient Access for Early-Stage Biotech Companies
Discover more like this
